Thomas Hope, MD, discusses personalizing therapy for patients with neuroendocrine tumors with Lutathera as well as the significance of somatostatin receptor PET to the treatment landscape.
Andrew E. Hendifar, MD, discusses clinical experience with a 92-gene assay and the importance of molecular classification in the NETs landscape.
Excitement surrounds systemic therapies for hepatocellular carcinoma, with 1 new drug recently approved, 2 agents pending FDA decisions, and later-stage clinical trials for multiple therapies on the horizon.
Lyudmila A. Bazhenova, MD, discusses the nondriver NSCLC population, the treatment strategies available for them, and challenges physicians continue to face with this subgroup of patients.
Jorge Garcia, MD, discusses how the field of bladder cancer has transformed with the FDA approval of pembrolizumab, and how oncologists should choose between 5 checkpoint inhibitors now available for the second-line setting and beyond.
Ramaswamy Govindan, MD, speaks to the rapid therapeutic changes and sequencing questions physicians are currently asking.
Dennis Scribner, MD, discusses the treatment landscape for patients with recurrent ovarian cancer and how PARP inhibitors have enhanced the treatment options for this population.
The safety and tolerability of chimeric antigen receptor T-cell therapy is being explored in an ongoing single-arm, phase I clinical trial for patients with advanced non–small cell lung cancer.
Daniel Morgensztern, MD, discusses both the single-agent and combination immunotherapy data in NSCLC and what researchers are poised to do next in the field.
Aarti Bhatia, MD, discusses newer single agents and combination treatments being investigated for patients with head and neck cancer.
Lynn Acton, MS, CCC (SLP) discusses the significance of swallowing modalities for patients with head and neck cancer during and after radiation therapy.
Jonathan Riess, MD, discusses the game-changing efficacy of osimertinib in NSCLC and its potential in combination, considering factors for choosing an EGFR TKI, and the burgeoning questions clinicians still have with the<em> EGFR</em>-mutant population.
Bradley J. Monk, MD, discusses his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.
Axel Grothey, MD, addresses the need for tailoring treatments for patients with mCRC in the first-line setting, the debate over tumor sidedness in mCRC, and what ongoing research in the field might reveal over the next year.
Rahmi Oklu, MD, PhD, sheds light on the various approaches physicians use to treat patients who have CRC with liver metastases.
Bert O’Neil, MD, discusses the need for novel treatments for patients with metastatic colorectal cancer as well as why researchers need to develop a deeper understanding of tumor biology.
Matthew Gubens, MD, sheds light on how far the field has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.
Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.
Immunotherapy has made a significant impact in the field of non–small cell lung cancer. However, as more research unravels, investigators are unsure which set of combinations will have the most positive effect on their patients with advanced disease.
Beyond hematologic malignancies, adoptive therapy could potentially be effective in solid tumors, such as head and neck cancer, according to early results of a clinical trial.
Leena Gandhi, MD, PhD, discusses the ongoing phase III ALEX study, which is exploring alectinib as a first-line treatment option for <em>ALK</em>-positive non–small cell lung cancer.
Mike Janicek, MD, sheds light on why physicians are slow to educate patients on genetic testing, the detection of genes aside from <em>BRCA1/2</em>, and the lesser-known benefits of getting genetic testing early on in a diagnosis.
Lyndsay J. Willmott, MD, discusses how PARP inhibitor approvals have impacted clinical practice and patient outcomes and quality of life in ovarian cancer.
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel has shown promising results in patients with diffuse large B-cell lymphoma, primary mediastinal lymphoma, and transformed follicular lymphoma, according to findings presented at the 2017 AACR Annual Meeting.
Heather Dalton, MD, discusses first-line treatment options currently available for patients, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.
The PD-1 and CTLA-4 inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced a 12% reduction in the risk of death versus nivolumab monotherapy in patients with treatment-naïve advanced melanoma.
Andre Goy, MD, highlights what researchers can expect next in the field of MCL in both the frontline and relapsed/refractory settings given the recent pivotal data from clinical trials.
The first-in-class IDO1 inhibitor epacadostat (INCB024360), currently being investigated in combination with the PD-1 inhibitor pembrolizumab (Keytruda), could be an exciting new FDA approval for patients with stage III/IV unresectable or metastatic melanoma.
Brian Hemphill, MD, provides insight on some of the challenges currently being faced in GI malignancies—specifically, colorectal cancer, pancreatic cancer, and gastic cancer—and how molecular profiles of tumors will dramatically change outcomes for these patients.
An investigational anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy demonstrated an objective response rate of 78% in patients with relapsed/refractory multiple myeloma.